Nemotan (Nimodipine)

Nimodipine, the active ingredient in Nemotan, is a calcium channel blocker presented as an oral tablet for oral use. It is employed to prevent cerebral vasospasm following subarachnoid hemorrhage, helping to maintain adequate cerebral blood flow in affected patients, particularly in neurosurgical settings.

GNH USA supplies Nemotan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. GNH USA also offers comprehensive regulatory support and customized logistics to meet the needs of global healthcare providers.

Nemotan, a calcium channel blocker, is used in conditions where cerebral vessel constriction can lead to serious complications. - Subarachnoid hemorrhage: prevents development of cerebral vasospasm and associated ischemic complications. - Delayed cerebral ischemia: improves cerebral blood flow to reduce risk of neurological deficits. - Neurosurgical patients at risk of vasospasm: supports vascular stability during postoperative recovery.

Common Side Effects: - Headache: mild to moderate intensity. - Hypotension: transient drop in blood pressure, especially when standing. - Nausea: occasional gastrointestinal upset. - Flushing: warm sensation with reddening of skin.

Serious or Rare Side Effects: - Severe hypotension: may require medical intervention. - Hepatic dysfunction: elevated liver enzymes. - Allergic reactions: rash, itching, or anaphylaxis in rare cases.

Before initiating therapy, consider the following precautions: - Dose adjustment in renal or hepatic impairment: reduce dose or monitor closely. - Avoid concomitant use with strong CYP3A4 inhibitors: may increase plasma levels. - Monitor blood pressure regularly: watch for symptomatic hypotension. - Use with caution in patients with pre‑existing hypotension: assess risk‑benefit. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Nimodipine may interact with several medicines; categorize as follows. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): can markedly increase nimodipine concentrations. - Other calcium channel blockers: additive hypotensive effect. - Grapefruit juice: may elevate drug levels.

Moderate Interactions (Monitor Closely):\n- Antihypertensives (e.g., ACE inhibitors, beta‑blockers): may enhance blood‑pressure lowering. - Diuretics: potential for excessive fluid loss and hypotension. - CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce efficacy by lowering drug levels.